Filing Details
- Accession Number:
- 0001559515-20-000002
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-05-15 17:19:17
- Reporting Period:
- 2020-05-13
- Accepted Time:
- 2020-05-15 17:19:17
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1270073 | Intercept Pharmaceuticals Inc. | ICPT | Pharmaceutical Preparations (2834) | 223868459 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1559537 | Paolo Fundaro | C/O Genextra S.p.a., Via G. De Grassi, 11 Milan L6 20123 | Yes | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock, Par Value $0.001 Per Share | Disposition | 2020-05-13 | 595,578 | $84.60 | 5,500,000 | No | 4 | S | Indirect | See Footnote |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Indirect | See Footnote |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock, Par Value $0.001 Per Share | 19,433 | Direct |
Footnotes
- These shares are held by Genextra S.p.A. Mr. Fundaro is the Chief Executive Officer of Genextra S.p.A. and, in such capacity, Mr. Fundaro exercises voting control over the shares of common stock owned by Genextra S.p.A and investment control over such shares as authorized by the board of Genextra S.p.A. Mr. Fundaro disclaims beneficial ownership with respect to any such shares, except to the extent of his pecuniary interest therein, if any.
- Genextra S.p.A. will apply the proceeds from the sale to reduce outstanding indebtedness under its margin loan secured by its shares of Intercept's common stock, and for general corporate purposes.